In our current study, we investigated the in vitro efficacy of CB-5083 in ovarian cancer and identified new strategies to enhance the cytotoxic effect of VCP inhibitors in combination with other compounds that modulate the unfolded protein response. This evidence concerns the gene VCP and ovarian carcinoma.